Listed

Tempest Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 15, 2019 and accepted by EDGAR at May 15, 2019, 07:23 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2019-01-01 to 2019-03-31−$10.7mus-gaap:OperatingIncomeLoss
Net income3 months2019-01-01 to 2019-03-31−$10.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-01-01 to 2019-03-31−$0.78us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2019-01-01 to 2019-03-31−$10.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2019-01-01 to 2019-03-31$10.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-03-31$65.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-03-31$72.7mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$74.3mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$9.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$10.6mus-gaap:Liabilities
Long-term debtAt period end2019-03-31$325.0kus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2019-03-31$191.0kus-gaap:DebtCurrent
Shareholders' equityAt period end2019-03-31$61.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-19-005038. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.